In earlier-stage testing, STC-15, an oral METTL3 inhibitor, produced durable tumor regressions across multiple sarcoma subtypes as monotherapy. Building on that signal, STORM Therapeutics has dosed the first patient in a Phase 2 study in selected sarcoma indications and closed a $56 million Series C to fund the program. The company is positioning the trial to support a potential accelerated approval pathway.
The core development is twofold: capital to extend runway and a move into a targeted Phase 2 designed around sarcoma biology rather than a broad solid tumor basket. STC-15 is described as first-in-class against METTL3, an epitranscriptomic regulator implicated in malignant progenitor cell differentiation. While detailed Phase 1 results have yet to be disclosed, STORM plans to present the dataset later this year, and the Phase 2 will test single-agent activity in predefined sarcoma cohorts with the explicit goal of generating registrationally relevant response and durability data. The investor syndicate—anchored by corporate venture arms including Pfizer Ventures, Taiho Ventures, and M Ventures—signals strategic interest in RNA-modifying enzyme targets and provides optionality for future partnering.
Strategically, selecting sarcoma for a first registration path is a calculated bet on rarity, heterogeneity, and regulatory precedent. Sarcomas lack consistent actionable drivers and have seen mixed returns from immunotherapy and targeted combinations, creating room for a differentiated monotherapy with a tolerable profile. A single-arm design keyed to objective response rate and duration could be sufficient for accelerated approval if the effect size is compelling and consistent across subtypes; the trade-off is heightened evidentiary scrutiny as FDA tightens expectations for confirmatory plans up front. The focus on a small-molecule oral agent also lowers operational friction compared to cell therapies or complex combinations, compressing site burden, CMC risk, and trial logistics during scale-up.
For sites, this program will likely concentrate activity in high-volume sarcoma centers with centralized pathology and imaging capabilities. Expect emphasis on archival tissue collection, fresh biopsies where feasible, and centralized lab support if STORM introduces methylation or transcriptomic signatures to enrich for METTL3 dependency. Turnaround time for any biomarker assays will be a gating factor for screening velocity. CROs with rare tumor expertise will be needed to manage parallel subtype cohorts, central radiology review, and the nuances of sarcoma response assessment. For sponsors and technology vendors, the study is a test case for integrating epitranscriptomic biomarkers into operational workflows without slowing enrollment, and for capturing patient-reported outcomes to contextualize durability in an oral monotherapy setting. Regulators will look for clarity on dose optimization, class-specific toxicities, and the confirmatory strategy—either within sarcoma or through expansion into additional METTL3-reliant tumors.
The next inflection point is the full Phase 1 readout, which needs to provide quantitative response rates, duration, and safety detail by histology to validate the mechanistic thesis. Watch for whether STORM introduces a biomarker-driven enrichment strategy, how many sarcoma subtypes the Phase 2 will run in parallel, and whether the protocol bakes in an adaptive design to graduate cohorts based on early activity. Geographic expansion to accelerate accrual, early conversations with FDA on confirmatory design, and initial combination plans—particularly with chemotherapy or TKIs in resistant settings—will signal how aggressively STORM intends to prosecute the opportunity. On the operational side, scaling manufacturing for an oral small molecule is straightforward, but supply chain, drug–drug interaction characterization, and long-term tolerability in a multi-line population remain open questions. The broader read-through: epitranscriptomic modulation is moving from concept to clinic, and sarcoma may be where the field first tests whether a precision biology built on RNA modification can satisfy modern accelerated approval standards.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
